Phase 2Completed
Phase 2a MIB-626 vs. Placebo COVID-19
A Phase 2a Randomized Controlled Trial of MIB-626 (NAD-boosting Drug) vs. Placebo in Adults With COVID-19 Infection and Early Acute Kidney Injury
- Sponsor
- Metro International Biotech, LLC (Industry)
- Enrolment
- 42 enrolled
- Conditions
- Covid19; Stage 1 Acute Kidney Injury
- Interventions
- MIB-626; Placebo; Home Treatment
- Ages
- adults, older adults
- Registry
- NCT05038488
From the registry
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuating the inflammatory response to the infection.
Primary outcomes
- Change from baseline in serum cystatin C levels